Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €126.67 EUR
Change Today +0.465 / 0.37%
Volume 0.0
SIQ On Other Exchanges
As of 3:05 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

sigma-aldrich (SIQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/15 - €131.55
52 Week Low
08/8/14 - €74.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIGMA-ALDRICH (SIQ)

sigma-aldrich (SIQ) Related Businessweek News

No Related Businessweek News Found

sigma-aldrich (SIQ) Details

Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. The company provides chemical products, reagents, and kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and diagnosis of disease; and as key components in pharmaceutical, diagnostics, and high technology manufacturing. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing. The company sells its products to pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies, and hospitals. Sigma-Aldrich Corporation was founded in 1951 and is based in St. Louis, Missouri.

9,400 Employees
Last Reported Date: 05/7/15
Founded in 1951

sigma-aldrich (SIQ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $485.4K
Executive Vice President and President of App...
Total Annual Compensation: $455.7K
Executive Vice President and President of SAF...
Total Annual Compensation: $404.2K
Compensation as of Fiscal Year 2014.

sigma-aldrich (SIQ) Key Developments

GenapSys, Inc. Partners with Sigma-Aldrich Corporation

GenapSys, Inc. has partnered with Sigma-Aldrich Corporation to co-market GenapSys' Gene Electronic Nano-Integrated Ultra-Sensitive (Genius(TM)) system, a personal deoxyribonucleic acid (DNA) sequencer.

Sigma-Aldrich Corporation Expands Analytical Portfolio with National Institute of Standards and Technology Standard Reference Materials

Sigma-Aldrich Corporation announced that the National Institute of Standards and Technology (NIST) has selected Sigma-Aldrich as the first licensed distributor of NIST Standard Reference Materials® (SRMs). This agreement enables Sigma-Aldrich to further expand its global analytical product line and make NIST reference materials readily available to customers worldwide. Sigma-Aldrich and NIST will also collaborate to develop new Standard Reference Materials for quantitative Nuclear Magnetic Resonance (qNMR). NIST's 1,300 Standard Reference Materials are used to perform instrument calibrations and measurement validation as part of overall quality assurance programs to verify the accuracy of specific measurements and to support the development of new measurement methods. Industry, academia, and government organizations use NIST SRMs to facilitate commerce and trade and to advance research and development.

Sigma-Aldrich Inks Agreement with XCell Science to Launch Genetically-Engineered Cells for Neurological Research

Sigma-Aldrich entered into an agreement with XCell Science to launch genetically engineered human neural differentiated cells for neurological disease research. The new products, in combination with SIAL's existing product portfolio, are expected to provide tools for the study of central nervous system disorders, such as Alzheimer's disease, Parkinson's disease, autism, schizophrenia, and amyotrophic lateral sclerosis, as well as for drug screening and toxicology applications.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIQ:GR €126.67 EUR +0.465

SIQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $194.55 USD +1.60
Dr Reddy's Laboratories Ltd 3,712 INR -36.75
International Flavors & Fragrances Inc $114.57 USD +0.87
UCB SA €66.84 EUR -0.16
Waters Corp $133.38 USD +2.80
View Industry Companies

Industry Analysis


Industry Average

Valuation SIQ Industry Range
Price/Earnings 33.6x
Price/Sales 6.0x
Price/Book 5.3x
Price/Cash Flow 33.4x
TEV/Sales 5.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA-ALDRICH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at